MedTrace Logo

Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases

NCT05260151 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 155

Last updated 2022-03-02

No results posted yet for this study

Summary

Tau protein has been identified as one of the key pathological features of Tau proteinopathies, such as Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD). Tau protein-targeted PET imaging can detect the amount and distribution of Tau protein deposition in human body, and has great research and application value in the diagnosis and evaluation of Tau protein disease. This study will be the first to introduce a complete quantitative, repeatable detection and analysis method in China. For the SV2a tracer \[18F\]MNI-1126, cross-sectional evaluation of its imaging in patients with Tau protein-related diseases and normal controls will be carried out. Later, longitudinal clinical symptoms and two tracers will be evaluated in patients with Tau protein-related diseases and normal controls.(\[18F\]APN1607 and \[18F\]MNI1126) Imaging follow-up to explore longitudinal changes in brain Tau protein deposition and synaptic density in Tau protein-related diseases, thus providing support for future clinical drug trials using imaging biomarkers.

Conditions

Sponsors & Collaborators

  • XINGIMAGING LLC

    collaborator UNKNOWN

  • H. Lundbeck A/S

    collaborator INDUSTRY

  • Millennium Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Biogen

    collaborator INDUSTRY

  • Hangzhou G-Bio Biotechnology Co., Ltd

    collaborator UNKNOWN

  • Xuanwu Hospital, Beijing

    lead OTHER

Principal Investigators

  • Biao Chen, M.D., Ph.D · Xuanwu Hospital, Beijing

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-18
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05260151 on ClinicalTrials.gov